Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Irene Robinson

  • Home
  • Author: Irene Robinson

UK insurers must maintain strong communication throughout second COVID-19 lockdown

A rare positive for insurers from the COVID-19 pandemic is that small and medium-sized enterprises (SMEs) in the UK believe their communication with regards to COVID-19 has been strong, and this will remain essential throughout this second lockdown, according to GlobalData, a leading data and analytics company. According to GlobalData’s 2020 UK SME Insurance Survey, 63.6% of all SMEs in the UK are […]
Read more

Pharmaceutical industry continues to bet big on AI

Declining pharmaceutical research and development (R&D) efficiency has been an ongoing problem in pharmaceutical sector. With emerging technologies reshaping various business, pharma is looking to capitalize on artificial intelligence (AI) to streamline operating models and address R&D’s productivity challenges, says GlobalData, a leading data and analytics company. According to a survey as part of GlobalData’s latest report, Digital Transformation and […]
Read more

Exit of Boston Scientific’s Lotus Edge will shake up US transcatheter aortic valve replacement market

Following the news that Boston Scientific is immediately retiring its Lotus transcatheter aortic valve replacement (TAVR) programme; Ashley Young, Senior Medical Devices Analyst at GlobalData, a leading data and analytics company, offers her view on the news: “Due to its minimally invasive nature, TAVR is a good alternative for patients who are not suitable candidates […]
Read more

Akebia’s vadadustat MACE profile remains unclear and US approval path in non-dialysis CKD anemia uncertain

Akebia Therapeutics presented additional data from its Phase III PRO2TECT trial at the 2020 American Society of Nephrology Kidney Week conference, that evaluated the efficacy and safety of vadadustat versus erythropoiesis stimulating agent (ESA) Aranesp (darbepoetin alfa) for the treatment of chronic kidney disease (CKD) anemia in adult non-dialysis patients. Despite the latest additional data, […]
Read more

Peripheral drug-coated balloon market makes strides, but may be hindered by COVID-19

While there has been movement within the drug-coated balloon (DCB) market, data and analytics company GlobalData expects that the ongoing COVID-19 pandemic will hinder the growth opportunities for DCBs, including Boston Scientific’s Ranger, which recently received FDA approval. Given the non-essential nature of the procedure and restrictions, GlobalData estimates that percutaneous transluminal angioplasty (PTA) balloon […]
Read more

First at-home COVID-19 self-testing kit will increase market share for POC tests

Following the Food and Drug Administration’s (FDA) authorization of the first rapid at-home COVID-19 self-testing kit; Dara Lo, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “Point-of-care (POC) COVID-19 tests provide results in near real-time. Coupled with the ability to self-test in the comfort and safety of one’s own home, this type […]
Read more

US, UK and Germany are top manufacturers for COVID-19 vaccines

Vaccine developers are selecting contract manufacturing organizations (CMOs) close to home for their COVID-19 vaccine, as the US, UK and Germany are the most popular supplier locations, says GlobalData, a leading data and analytics company. Johanna Swanson, MBA, Product Manager at GlobalData, comments: “These supply chains contrast with the general trend within the pharma industry to […]
Read more

BrainStorm’s NurOwn fails Phase III trial, demonstrating the struggle to develop effective ALS treatment

Following Brainstorm Cell Therapeutics announcement of topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy NurOwn; Sarah Elsayed, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view on the opportunities and challenges in this market: “NurOwn is the second pipeline drug to fail a clinical trial for ALS this year, […]
Read more

COVID-19 vaccine production driving contract service agreements for recombinant vector vaccines

COVID-19 is driving many small pharma companies that do not have the expertise or funds to run their own manufacturing facilities to outsource production. COVID-19 vaccine developers are signing contract service agreements at an unprecedented rate, as pharma companies have publicly revealed 42 contract manufacturing service agreements for 28 unique pipeline COVID-19 vaccines, as manufacturing companies […]
Read more

Kala Pharmaceuticals should focus on educating ophthalmologists and having a favorable price point for Eysuvis

The US Food and Drug Administration (FDA) recently announced the approval of Kala Pharmaceuticals’ Eysuvis, a topical steroid (0.25% loteprednol etabonate ophthalmic suspension), for short-term treatment of the signs and symptoms of dry eye syndrome (DES). In order to smoothen market access for this new therapy and facilitate its uptake, Kala Pharmaceuticals will need to […]
Read more

Moderna and Pfizer raise the bar for COVID-19 vaccines and may ward off competing candidates in development

Following the news that Moderna has announced its COVID-19 vaccine, mRNA-1273, is 94.5% effective in first interim data readout; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology at GlobalData, a leading data and analytics company, offers his view: “While the efficacy of Moderna’s offering is slightly higher than that reported for Pfizer/BioNTech’s candidate, the […]
Read more

Growth of T2D market driven by increasing diagnosed prevalence of disease and emergence of novel pipeline agents

Type 2 diabetes (T2D) is a crowded and competitive landscape, with market growth primarily driven by an increasing diagnosed prevalent population across nine major markets (9MM*) and the emergence of novel pipeline agents, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Type 2 Diabetes: Global Drug Forecast and Market Analysis to 2029’, reveals […]
Read more

Global deal activity down by 4.5% in October 2020

A total of 6,304 deals were announced globally during October 2020, which is a decrease of 4.5% over the 6,598 deals announced during September, according to GlobalData, a leading data and analytics company. An analysis of GlobalData’s Financial Deals Database revealed that the deal volume during October remained below the monthly average of Q3 2020. […]
Read more

Diabetes market continues to evolve rapidly

Across the seven major markets* (7MM), the diagnosed prevalence of type 1 and 2 diabetes (T1D) was approximately 3.7 million and 49.7 million, respectively, in 2020 – according to data and analytics company GlobalData. This is expected to grow to more than 4.3 million by 2025 for Type 1 and 54.4 million for Type 2 […]
Read more

Global refinery maintenance activities are gradually getting back on track

Refiners across the globe were severely impacted by COVID-19, which destroyed demand, reduced operations in several refineries and even compelled them to suspend operations. Despite unfavorable conditions in the first three quarters of 2020, refiners are getting back to normalcy with seemingly improving market scenario, says GlobalData, a leading data and analytics company. In the […]
Read more
1 … 3 4 5 6 7 … 15